Tyra Biosciences (TYRA) Expected to Announce Earnings on Thursday

Key Points

• Tyra Biosciences will report Q1 2026 results before the market opens on May 14; analysts expect EPS of ($0.60) and the company missed the prior quarter (reported ($0.57) vs. consensus ($0.54)).
• Wall Street has a consensus rating of Moderate Buy with an average target of $46.50, though views are mixed — e.g., Guggenheim rates it Buy with a $54 target while some firms carry Sell ratings.
• TYRA trades near $33.80 with a $2.01 billion market cap and a one‑year range of $8.75–$40.65; insiders own 12.5% (a director recently sold shares) and institutions hold about 84% of the stock.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Tyra Biosciences to post earnings of ($0.60) per share for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Tyra Biosciences Price Performance

TYRA opened at $33.80 on Thursday. The business has a fifty day simple moving average of $35.97 and a 200 day simple moving average of $28.07. The company has a market capitalization of $2.01 billion, a PE ratio of -16.82 and a beta of 0.79. Tyra Biosciences has a 1 year low of $8.75 and a 1 year high of $40.65.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TYRA. Wall Street Zen downgraded Tyra Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, January 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Tyra Biosciences in a research note on Monday, April 20th. Guggenheim began coverage on Tyra Biosciences in a research note on Tuesday, April 14th. They issued a "buy" rating and a $54.00 price target for the company. HC Wainwright boosted their price target on Tyra Biosciences from $30.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, February 17th. Finally, Wedbush boosted their price target on Tyra Biosciences from $37.00 to $53.00 and gave the company an "outperform" rating in a research note on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $46.50.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Gilla Kaplan sold 14,295 shares of the company's stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total transaction of $528,486.15. Following the completion of the sale, the director directly owned 28,231 shares in the company, valued at approximately $1,043,700.07. This represents a 33.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 12.50% of the company's stock.

Institutional Trading of Tyra Biosciences

A number of institutional investors have recently modified their holdings of the stock. Commodore Capital LP lifted its position in shares of Tyra Biosciences by 226.3% during the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company's stock valued at $29,667,000 after acquiring an additional 2,150,000 shares during the period. Janus Henderson Group PLC lifted its position in shares of Tyra Biosciences by 2.1% during the 4th quarter. Janus Henderson Group PLC now owns 2,935,442 shares of the company's stock valued at $77,085,000 after acquiring an additional 60,638 shares during the period. Farallon Capital Management LLC lifted its position in shares of Tyra Biosciences by 80.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company's stock valued at $54,337,000 after acquiring an additional 923,000 shares during the period. Vanguard Group Inc. lifted its position in shares of Tyra Biosciences by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company's stock valued at $21,267,000 after acquiring an additional 118,492 shares during the period. Finally, Caligan Partners LP lifted its position in shares of Tyra Biosciences by 35.5% during the 4th quarter. Caligan Partners LP now owns 944,257 shares of the company's stock valued at $24,825,000 after acquiring an additional 247,432 shares during the period. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.